In previous publications, a team of scientists led by Professor Anette-Gabriele Ziegler had already demonstrated an association between infections in early childhood and the development of type 1 diabetes. The highest risk for type 1 diabetes was observed in children with repeated respiratory infections in the first six months of life.
The current study showed that the risk of developing celiac disease is particularly high when gastrointestinal tract infections occur during the first year of life. To a lesser extent, an increased risk of disease was also demonstrated in connection with early respiratory tract infections. “Our data do not allow a conclusion whether the observed associations are causal or are based on changes in the microbiome or specific immune responses”, said first author Dr. Andreas Beyerlein, commenting on the results. “However, it seems that the increased risk of celiac disease is associated with a permanent inflammation of the gastrointestinal tract in early childhood and is not caused by a specific viral or bacterial pathogen.”
The scientists analyzed fully anonymized data provided by the Bavarian Association of Statutory Health Insurance Physicians (Kassenärztliche Vereinigung Bayern) of 295,420 children who were born between 2005 and 2007. Medically attended infections from birth until a median age of 8.5 years were considered in the analysis. A total of 853 children developed gluten intolerance, equivalent to 0.3 percent.
Beyerlein, A. et al. (2017): Infections in early life and development of celiac disease, American Journal of Epidemiology, DOI: 10.1093/aje/kwx190
Beyerlein, A. et al. (2016): Infections in early life and development of type 1 diabetes, JAMA, DOI: 10.1001/jama.2016. 2181
Beyerlein, A. et al. (2013): Respiratory Infections in Early Life and the Development of Islet Autoimmunity in Children at Increased Type 1 Diabetes Risk, JAMA Pediatrics, DOI:10.1001/jamapediatrics.2013.158
The Helmholtz Zentrum München, the German Research Center for Environmental Health, pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München is headquartered in Neuherberg in the north of Munich and has about 2,300 staff members. It is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members.
The Institute of Diabetes Research (IDF) focuses on the understanding of the natural history of type 1 diabetes, on the identification of mechanisms and predictive markers of the disease, and the translation of findings into trials to prevent type 1 diabetes in man. In particular, the institute’s aim is to develop an immune tolerance using antigen-based therapy. The IDF conducts long-term studies to examine the link between genes, environmental factors and the immune system for the pathogenesis of type 1 diabetes. Findings of the BABYDIAB study, which was established in 1989 as the world’s first prospective birth cohort study, identified the first two years of life as being most susceptible for the initiation of type 1 diabetes associated autoimmunity. The Fr1da study is the first population-based approach for the early diagnosis type 1 diabetes associated autoimmunity in childhood. The IDF is part of the Helmholtz Diabetes Center (HDC).
The German Center for Diabetes Research (DZD) is a national association that brings together experts in the field of diabetes research and combines basic research, translational research, epidemiology and clinical applications. The aim is to develop novel strategies for personalized prevention and treatment of diabetes. Members are Helmholtz Zentrum München – German Research Center for Environmental Health, the German Diabetes Center in Düsseldorf, the German Institute of Human Nutrition in Potsdam-Rehbrücke, the Paul Langerhans Institute Dresden of the Helmholtz Zentrum München at the University Medical Center Carl Gustav Carus of the TU Dresden and the Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Zentrum München at the Eberhard-Karls-University of Tuebingen together with associated partners at the Universities in Heidelberg, Cologne, Leipzig, Lübeck and Munich.
Contact for the media:
Claudia Pecher, Helmholtz Zentrum München – German Research Center for Environmental Health, Institute of Diabetes Research, Heidemannstr. 1, 80939 München – Tel. +49 89 3187 2547 – E-mail:
Scientific Contact at Helmholtz Zentrum München:
PD Dr. Andreas Beyerlein, Helmholtz Zentrum München – German Research Center for Environmental Health, Institute of Diabetes Research, Heidemannstr. 1, 80939 München – Tel. +49 89 3068 5578, E-mail: